ADC Therapeutics SA
(NYSE : ADCT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.68%145.650.7%$932.14m
PFEPfizer Inc. 0.84%36.060.9%$892.16m
MRKMerck & Co., Inc. -0.24%82.950.7%$692.55m
ABBVAbbVie, Inc. 0.35%86.211.9%$677.02m
BMYBristol-Myers Squibb Co. 2.15%59.501.0%$637.89m
LLYEli Lilly & Co. 0.97%150.261.1%$561.78m
AZNAstraZeneca Plc 2.47%55.511.2%$257.73m
NVSNovartis AG 0.96%87.130.2%$163.92m
GSKGlaxoSmithKline Plc 1.12%37.800.2%$109.18m
PRNBPrincipia Biopharma, Inc. 0.10%100.050.0%$86.76m
NVONovo Nordisk A/S 1.13%69.040.1%$57.64m
RGENRepligen Corp. 3.12%144.307.1%$49.54m
SNYSanofi -0.02%50.780.2%$49.00m
RPRXRoyalty Pharma Plc -0.40%40.070.2%$47.01m
OPKOPKO Health, Inc. 4.89%3.2211.2%$43.56m

Company Profile

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its products include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.